TABLE 3.
Multivariate logistic regression predicting the likelihood of treatment initiation based on age, gender, drug type, metastatic disease, marker or targetable mutation, supporting evidence and planned financing source (n = 708).
| B | SE | Wald | df | p-value | Odds ratio | 95% CI for odds ratio | ||
| Lower | Upper | |||||||
| Age | 0.013 | 0.009 | 2.285 | 1 | 0.131 | 1.013 | 0.966 | 1.031 |
| Gender | ||||||||
| Male | 0.458 | 0.252 | 3.292 | 1 | 0.700 | 1.580 | 0.964 | 2.591 |
| Drug type | ||||||||
| Targeted therapy | −0.898 | 0.320 | 7.882 | 1 | 0.005 | 0.407 | 0.218 | 0.762 |
| Immunotherapy | −0.221 | 0.378 | 0.340 | 1 | 0.560 | 0.802 | 0.382 | 1.683 |
| Metastatic disease | 0.092 | 0.322 | 0.082 | 1 | 0.775 | 0.912 | 0.485 | 1.715 |
| Marker | 0.275 | 0.277 | 0.991 | 1 | 0.320 | 1.317 | 0.766 | 2.265 |
| Supporting evidence | ||||||||
| Sufficient | −0.086 | 0.458 | 0.035 | 1 | 0.852 | 0.918 | 0.374 | 2.252 |
| Limited | 0.659 | 0.444 | 2.203 | 1 | 0.138 | 1.933 | 0.810 | 4.617 |
| Planned Financing Source | ||||||||
| Expanded access | 0.511 | 0.304 | 2.829 | 1 | 0.093 | 1.668 | 0.919 | 3.026 |
| No source | −0.916 | 0.262 | 12.252 | 1 | <0.0005 | 0.400 | 0.240 | 0.668 |
Gender is for Males compared to Females.